Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 2
1951 5
1953 4
1954 4
1955 3
1956 1
1961 2
1962 2
1980 1
1981 1
1984 1
1985 1
1986 6
1987 2
1988 6
1989 6
1990 11
1991 11
1992 9
1993 7
1994 11
1995 9
1996 4
1997 11
1998 8
1999 8
2000 8
2001 5
2002 7
2003 10
2004 1
2005 5
2006 1
2007 4
2008 2
2009 2
2010 3
2011 1
2012 6
2013 1
2014 1
2015 1
2016 4
2017 3
2018 3
2020 2
2021 4
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 8120557

210 results

Results by year

Filters applied: . Clear all
Page 1
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A, Reiser M, Wickramanayake PD, Rueffer U, Draube A, Söhngen D, Tesch H, Wolf J, Diehl V, Engert A. Josting A, et al. Leuk Lymphoma. 2000 Mar;37(1-2):115-23. doi: 10.3109/10428190009057634. Leuk Lymphoma. 2000. PMID: 10721775 Clinical Trial.
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Sieber M, et al. J Clin Oncol. 2002 Jan 15;20(2):476-84. doi: 10.1200/JCO.2002.20.2.476. J Clin Oncol. 2002. PMID: 11786577 Clinical Trial.
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Müller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Schmitz N, et al. Lancet. 2002 Jun 15;359(9323):2065-71. doi: 10.1016/S0140-6736(02)08938-9. Lancet. 2002. PMID: 12086759 Clinical Trial.
High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F. Martelli M, et al. J Clin Oncol. 1996 Feb;14(2):534-42. doi: 10.1200/JCO.1996.14.2.534. J Clin Oncol. 1996. PMID: 8636768 Clinical Trial.
210 results